You are viewing the site in preview mode

Skip to main content

Table 3 Timeline of assessments

From: Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial

Assessments Screening Randomization Baselined Day 1d Day 2 Day 3 Day 4 Day 7
Experimental arm: rapid micro-induction
(E stands for experimental arm assessments) 		     
Control arm: standard induction
(C stands for control arm assessments) 		      
Informed consent form E
C 		       
Physical examination E
C 		  E
C 		E
C 		E
C 		E
C 		E  
Medical history E
C 		       
Pregnancy test E
C 		       
Blood testsa E
C 		       
Viral profileb E
C 		       
Urine drug screens E
C 		  E
C 		  C E   
Opiate treatment index (OTI)—health section    E
C 		     
Treatment outcomes profile (TOP)    E
C 		  C E   
Clinical Opiate Withdrawal Scale (COWS)    Ec
Cc 		Ec
Cc 		Ec    
Numeric Rating Scale for craving    Ec
Cc 		Ec
Cc 		Ec    
Numeric Rating Scale for pain    Ec
Cc 		Ec
Cc 		Ec    
Treatment Perceptions Questionnaire (TPQ)      C E   
Assessment of treatment retention         E
C
Adverse event report form    E
C 		E
C 		E
C 		E
C 		E  
  1. aComplete blood count (CBC), Extended lytes, Liver function
  2. bHepC serology, HepB antigen, HIV Elisa
  3. cThe COWS and Numeric Rating Scales for craving and pain will be administered at baseline, every 1.5 h during the abstinence period (control arm only), and throughout the induction process for both arms (days 1 to 2 of the experimental arm, and day 1 of the control arm)—specifically, immediately before each dose of buprenorphine/naloxone, and 1 to 1.5 h after each dose of buprenorphine/naloxone
  4. dBaseline and day 1 assessments may be done on the same day, depending on the time of day the participants are recruited in the study and the state they are in when they are recruited
Back to article page

Addiction Science & Clinical Practice

ISSN: 1940-0640